|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We examined 25 cases of colorectal lymphoma with DLBCL-like morphology and classified them into germinal center B-cell like (GCB)/non-GCB subgroups by immunohistochemistry (IHC) for CD10, bcl-6 and MUM1, or into double-expressor (DE)/non-DE subgroups by IHC for bcl-2 and c-myc.
|
31734190 |
2020 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MYD88 and CD79B mutations were identified in 29.6% and 12.3%, , MYC, BCL2, and BCL6 rearrangements in 10.6%, 13.6%, and 20.3%, and EBV in 11.7% of diffuse large B-cell lymphomas, respectively.
|
31123031 |
2020 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The present study analysed the genomic alterations and protein expression levels of MYC, BCL2 and BCL6 using FISH and IHC in Chinese patients with DLBCL.We assessed the frequency, clinicopathological features and the prognostic impacts of DHL and DEL in a cohort of de novo DLBCL patients and evaluated the role of each genetic translocation separately and in combination in order to provide reliable conclusions and practical recommendations for diagnostic workups and prognostic predictions.
|
31615842 |
2020 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CONCLUSIONS A retrospective study of 46 patients with primary DLBCL of the breast showed that >3 cycles of chemotherapy and expression of Bcl-6 resulted in improved OS and PFS.
|
31734687 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The rearrangements of C-MYC, BCL2 and/or BCL6 which are common in diffuse large B-cell lymphoma (DLBCL) are typically absent in PLMBCL.
|
31728727 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently, high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements have been categorized separately from diffuse large B-cell lymphoma or BL.
|
31229156 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, the subgroup analyses show that BCL6 rearrangement is prognostic only in DLBCLs treated with rituximab-containing regimens.
|
30719149 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We identified 122 patients diagnosed as having large B-cell lymphoma (44, MYC-negative; 29, MYC-EC; 23, MYC rearrangement; 22, MYC and BCL2 rearrangements; 4, MYC, BCL2, and BCL6 rearrangements). p53 expression significantly correlated with DLBCL with abnormal MYC status (MYC-EC, MYC rearrangement, and MYC overexpression), but adverse p53 prognostic effect was only seen with MYC-rearranged lymphoma.
|
30496802 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MEF2B is a member of the BCL6 gene transcriptional complex and induces its expression in diffuse large B-cell lymphoma of the germinal center B-cell-like type.
|
30446717 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Double/triple-hit lymphomas (DHL/THL) account for 5-10% of diffuse large B cell lymphoma (DLBCL) with rearrangement of MYC and BCL2 and/or BCL6 resulting in MYC overexpression.
|
31288832 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical Significance of <i>BCL2</i>, C-<i>MYC</i>, and <i>BCL6</i> Genetic Abnormalities, Epstein-Barr Virus Infection, CD5 Protein Expression, Germinal Center B Cell/Non-Germinal Center B-Cell Subtypes, Co-expression of MYC/BCL2 Proteins and Co-expression of MYC/BCL2/BCL6 Proteins in Diffuse Large B-Cell Lymphoma: A Clinical and Pathological Correlation Study of 120 Patients.
|
31171907 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Possible prognostic significance of MYC, BCL2, and/or BCL6 rearrangements may be important given what we know about their impact in systemic DLBCL, but we have limited knowledge about the status of double or triple hit molecular changes in PCNSL.
|
30306208 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
High-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/THs) include a group of diffuse large B-cell lymphomas (DLBCLs) with inferior outcomes after standard chemoimmunotherapy.
|
31527075 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Regarding concurrent expression of MYC and BCL2 and/or BCL6 (double expressors (DE) and triple expressors (TE)), more DE and TE cases were found in the HGBL/DLBCL group than in the DLBCL group (25.53% vs 8.47%, p < 0.001, for DE cases and 55.32% vs 6.21%, p < 0.001, for TE cases).
|
31518494 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our findings describe AIP as a positive regulator of BCL6 expression with implications for the pathobiology of diffuse large B cell lymphoma.
|
31042473 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Correction: MYC Expression in Concert With BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified.
|
30586419 |
2018 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, immunohistochemical detection of C-MYC, BCL-2, and BCL-6 are useful in diagnosis and prognosis of DLBCL.
|
30666200 |
2018 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Double-hit lymphoma (DHL), defined as a dual rearrangement of MYC and BCL2 and/or B-cell CLL/lymphoma 6 (BCL6) genes, is an uncommon subset accounting for 5% to 7% of all diffuse large B-cell lymphomas (DLBCLs), and long-term survivors are rare.
|
30252929 |
2018 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Compared with nodal DLBCL (9% to 14%), the PCDLBCL-LT patients had a high incidence of MYC rearrangements (32%), but only 2 patients (4%) had a second hit, both with BCL6.
|
30113335 |
2018 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP.
|
30287880 |
2018 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, we have developed potent and selective BCL6 inhibitors and a BCL6 PROTAC that effectively degraded BCL6, but both modalities failed to induce a significant phenotypic response in DLBCL despite achieving cellular concentrations.
|
30335946 |
2018 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
WTAP is a client protein of Hsp90 and can appear in a complex with BCL6 and Hsp90 in DLBCL.
|
30143009 |
2018 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
While immunohistochemical (CD10, IRF4/MUM1, Ki67, BCL2, BCL6) and genetic profiles (translocations of BCL2, BCL6 and MYC) delineate FL1-3A from FL3B and DLBCL/FL3B, significant differences were observed between FL1/2 and FL3A upon gene expression profiling.
|
29567771 |
2018 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
BCL6-i showed intracellular PPI inhibitory activity between BCL6 and its corepressors, thus resulting in BCL6-dependent DLBCL cell growth inhibition.
|
29293322 |
2018 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical staining was performed to detect MYC, BCL-2 and BCL-6 expression in 212 patients with newly diagnosed DLBCL and assess the prognostic effects of BCL-2 and BCL-6 expression.
|
29983382 |
2018 |